Travaux scientifiques

Uzm. Dr. Mert Kaşkal

42 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Cytotoxic effect of famotidine in breast adenocarcinoma cells line

    Northern Clinics of Istanbul, 2026

    DOI 10.14744/nci.2026.55899 PMID 41940059 Texte intégral en libre accèsSource : OpenAlex

  2. Cross-exclusion of patients with chronic obstructive pulmonary disease and heart failure in randomized controlled drug trials

    Respiratory Medicine, 2026

    DOI 10.1016/j.rmed.2026.108781 PMID 41862104 Source : ORCID

  3. Albumin levels and risk of early cardiovascular complications after endovascular thrombectomy for acute ischaemic stroke

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-50280-0 PMID 42032112 Texte intégral en libre accèsSource : ORCID

  4. Long-term prognosis in Takotsubo syndrome compared to heart failure: observations from a global federated research network

    ESC Heart Failure, 2026

    DOI 10.1093/eschf/xvag065 PMID 41761829 2 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  5. Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    BMC Pulmonary Medicine, 2026

    DOI 10.1186/s12890-026-04216-z PMID 41782097 Texte intégral en libre accèsSource : ORCID

  6. Prognostic Impact of New-Onset Atrial Fibrillation After Cardiac Arrest: Observations From a Federated Research Network

    Journal of Cardiovascular Electrophysiology, 2026

    DOI 10.1111/jce.70288 PMID 41668553 Texte intégral en libre accèsSource : ORCID

  7. Additional file 2 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985912 Texte intégral en libre accèsSource : OpenAlex

  8. Additional file 1 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985909 Texte intégral en libre accèsSource : OpenAlex

  9. Additional file 6 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985924 Texte intégral en libre accèsSource : OpenAlex

  10. Additional file 7 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985927 Texte intégral en libre accèsSource : OpenAlex

  11. Additional file 4 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985918 Texte intégral en libre accèsSource : OpenAlex

  12. Additional file 5 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985921.v1 Texte intégral en libre accèsSource : OpenAlex

  13. Additional file 8 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985930.v1 Texte intégral en libre accèsSource : OpenAlex

  14. Additional file 3 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985915 Texte intégral en libre accèsSource : OpenAlex

  15. The use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits

    Current Opinion in Clinical Nutrition & Metabolic Care, 2026

    DOI 10.1097/mco.0000000000001262 PMID 42935438 Source : OpenAlex

  16. Frailty and Poor Sleep Patterns

    JACC: Asia, 2025

    DOI 10.1016/j.jacasi.2025.09.004 PMID 41198377 Texte intégral en libre accèsSource : ORCID

  17. The clinical impact of chronopharmacology on current medicine

    Naunyn-Schmiedeberg's Archives of Pharmacology, 2025

    DOI 10.1007/s00210-025-03788-7 PMID 39792169 11 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  18. The risk of acute exacerbations of chronic obstructive pulmonary disease following acute myocardial infarction

    European Respiratory Journal, 2025

    DOI 10.1183/13993003.congress-2025.pa3477 Source : OpenAlex

  19. Risk of adverse events in takotsubo syndrome compared to heart failure: observations from a global federated network

    European Heart Journal, 2025

    DOI 10.1093/eurheartj/ehaf784.1082 Source : OpenAlex

  20. Use of lipid-lowering drugs in restricted health access settings: Results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study

    Vascular Pharmacology, 2024

    DOI 10.1016/j.vph.2024.107382 PMID 38815702 6 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  21. Assessing effects of tamoxifen on tolerance, dependence, and glutamate and glutamine levels in frontal cortex and hippocampus in chronic morphine treatment

    Behavioural Brain Research, 2024

    DOI 10.1016/j.bbr.2024.114897 PMID 38331101 1 citation (Europe PMC) Source : ORCID

  22. Evaluation of the teratogenic effects of pregabalin usage during pregnancy: A multicenter case-control study

    Northern Clinics of Istanbul, 2024

    DOI 10.14744/nci.2024.57702 PMID 39431036 Texte intégral en libre accèsSource : ORCID

  23. Comparison of primary care prescriptions for old and very old hypertensive patients

    TURKISH JOURNAL OF MEDICAL SCIENCES, 2023

    DOI 10.55730/1300-0144.5618 PMID 37476867 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  24. Favipiravir Does Not Appear to Be a Major Teratogen: Case Series from Türkiye

    Journal of Gynecology Obstetrics and Human Reproduction, 2023

    DOI 10.1016/j.jogoh.2023.102693 PMID 37984519 4 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

  25. Favipiravir Does Not Appear to Be a Major Teratogen: Case Series from Türkiye

    Ssrn, 2023

    DOI 10.2139/ssrn.4443306 Texte intégral en libre accèsSource : Europe PMC

  26. Evaluation of Stress Response in Middle-Aged Male Diabetic Hypertensive Patients

    Journal of Clinical Endocrinology and Metabolism, 2023

    DOI 10.1210/clinem/dgad122 PMID 36880261 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  27. Iohexol exposure in the first trimester of the pregnancy, a case report

    Neurotoxicology and Teratology, 2023

    DOI 10.1016/j.ntt.2023.107229 1 citation (OpenAlex) Source : OpenAlex

  28. The evaluation of drug adherence in primary health care : A single center epidemiological study

    Dspace Repository (Marmara Üniversitesi), 2023

    Source : OpenAlex

  29. Gebeliğin ilk trimestırında iohexol maruziyeti, vaka sunumu

    Dspace Repository (Marmara Üniversitesi), 2023

    Source : OpenAlex

  30. Efficacy of topical dexamethasone eye drops in preventing ocular inflammation and cystoid macular edema following uncomplicated cataract surgery with or without injection of a single dose perioperative subtenon triamcinolone acetonide

    Cutaneous and Ocular Toxicology, 2022

    DOI 10.1080/15569527.2022.2136193 PMID 36308286 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  31. Long term results of three anti-vascular endothelial growth factor agents in pachychoroid neovasculopathy

    Cutaneous and Ocular Toxicology, 2022

    DOI 10.1080/15569527.2022.2068150 PMID 35579866 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  32. Brief communication: A case of cyclophosphamide exposure in the first trimester of pregnancy

    European Journal of Obstetrics and Gynecology and Reproductive Biology, 2022

    DOI 10.1016/j.ejogrb.2022.03.029 PMID 35341650 Texte intégral en libre accèsSource : ORCID

  33. THE INFLUENCE OF PHARMACOGENETICS IN THE CLINICAL USE OF ANTIDEPRESSANTS

    Kocatepe Tıp Dergisi, 2022

    DOI 10.18229/kocatepetip.892349 Texte intégral en libre accèsSource : ORCID

  34. Evaluation of Risk Factors Associated With Antihypertensive Treatment Success Employing Data Mining Techniques

    Journal of Cardiovascular Pharmacology and Therapeutics, 2022

    DOI 10.1177/10742484221136758 PMID 36324213 Texte intégral en libre accèsSource : ORCID

  35. Renal pathologies and mesalazine use in pregnancy

    Neurotoxicology and Teratology, 2022

    Source : ORCID

  36. Gebelikte mesalazin kullanımı ve renal patolojiler

    Dspace Repository (Marmara Üniversitesi), 2022

    Texte intégral en libre accèsSource : OpenAlex

  37. Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial

    Pharmaceutics, 2021

    DOI 10.3390/pharmaceutics13111768 PMID 34834183 15 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  38. "Evaluation of the Effect of a Mobile Phone Application on Treatment Success and Drug Adherence in Hypertensive Patients"

    Biomedical Journal of Scientific & Technical Research, 2021

    DOI 10.26717/bjstr.2021.39.006373 Texte intégral en libre accèsSource : ORCID

  39. A case of pancreatic enzyme elevation due to use of statins

    DergiPark (Istanbul University), 2021

    Texte intégral en libre accèsSource : OpenAlex

  40. Chrono-pharmacological effects of antihypertensive drugs

    European Heart Journal, 2020

    DOI 10.1093/eurheartj/ehaa213 PMID 32298408 5 citations (Europe PMC) Source : ORCID

  41. Hypersensitivity reaction induced with renin-angiotensin-aldosterone system blocker antihypertensive agents

    Demiroglu Science University Florence Nightingale Journal of Medicine, 2020

    DOI 10.5606/fng.btd.2020.25013 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID

  42. Percutaneous cholecystostomy: A curative treatment modality forelderly & high asa score acute cholecystitis patients,Perkütan kolesistostomi: Yaşlı ve yüksek ASA skorlu akut kolesistitli hastalarda küratif tedavi yöntemi

    Ulusal Travma Ve Acil Cerrahi Dergisi, 2017

    DOI 10.5505/tjtes.2016.26053 PMID 28261768 7 citations (Europe PMC) Source : ORCID